Aureon Laboratories Completes Initial Study with AstraZeneca PLC Using Predictive Pathology to Stratify Patient Risk for Non-Small Cell Lung Cancer
YONKERS, N.Y.--(BUSINESS WIRE)--Aureon Laboratories, Inc. today announced the successful completion of a development project with AstraZeneca designed to identify patients with non-small-cell lung cancer that may benefit from treatment with IRESSA®.